Moderna’s Skin Cancer Vaccine – Plus Immunotherapy – Shows Promise Against Melanoma
Source: Health News Care, February 2023
An experimental skin cancer vaccine is poised for the fast track.
Moderna’s mRNA vaccine for melanoma, in combination with an immunotherapy drug by Merck, received a special “breakthrough therapy” designation from the U.S. Food and Drug Administration (FDA).
That opens the door for expedited development and review. It also shows the promise of mRNA technology to treat the deadliest skin cancer — and potentially, other cancers too.
